Cirrhosis News and Research

Latest Cirrhosis News and Research

Simple traffic light test helps reduce drinking rates in people with risk of liver disease

A simple 'traffic light' test that detects hidden liver fibrosis and cirrhosis in high risk populations could reduce harmful drinking rates and potentially prevent hundreds of alcohol-related deaths a year.

25 Sep 2013

Smartphone app can quickly screen for cognitive dysfunction in patients with cirrhosis

A smartphone app can quickly screen for cognitive dysfunction often found in patients with cirrhosis, according to a new Virginia Commonwealth University study. The cognitive dysfunction, known as minimal hepatic encephalopathy (MHE), has been difficult to diagnose.

19 Sep 2013

Boehringer Ingelheim completes patient enrolment for interferon-free hepatitis C treatment

Boehringer Ingelheim today announced the completion of patient enrolment for a Phase IIa clinical trial investigating a new interferon-free, all-oral, direct-acting antiviral combination treatment for patients with genotype-1a chronic hepatitis C virus infection.

10 Sep 2013

Hepatitis C services in the UK: an interview with Louise Campbell, senior liver nurse at Imperial College Healthcare NHS Trust

Within the UK there are several centres whose nurse specialists work to a best practice model, delivering care and achieving outcomes which are extremely high in areas of patient retention, adherence to medication and completion of the treatment regimen. With this they achieve cure rates which are some of the highest in the World.

9 Sep 2013

Peru: Liver cancer affects young people and children who do not have related risk factors

Liver cancer is the sixth most common cancer worldwide and the third most deadly. It mainly affects men over the age of 40, most often with cirrhosis or hepatitis B or C. But in Peru, it also uncharacteristically affects young people, even children, who do not have the identified related risk factors.

5 Sep 2013

World Bank Group, IHME reports to help policymakers tackle health issues facing countries

In the Middle East and North Africa, heart disease, stroke, and diabetes are causing a massive amount of premature death and disability. People in Latin America and the Caribbean are living longer on the whole, yet they face increasing threats from chronic diseases. Mortality has declined in many South Asian countries, yet the number of deaths by non-communicable diseases and self-harm has skyrocketed since 1990.

5 Sep 2013

Blocking a protein helps virus to thrive and restore immune function to fight HCV infection

The hepatitis C virus hijacks the body's immune system, leaving T cells unable to function. A new study in animal models suggests that blocking a protein that helps the virus thrive could restore immune function, allowing the body to fight infection. The work, led by teams at The Research Institute at Nationwide Children's Hospital and Emory University, was published online Aug. 26 in the Proceedings of the National Academy of Sciences.

4 Sep 2013

Argininosuccinic aciduria (ASA) and gene therapy: an interview with Dr Julien Baruteau, UCL Institute for Women's Health, London

This rare genetic condition can theoretically affect patients at any age but symptoms are more often observed in childhood and even uncommonly during the first days of life.

2 Sep 2013

Boehringer Ingelheim completes patient enrolment of two pivotal Phase III interferon-free hepatitis C clinical trials

Boehringer Ingelheim today announced that enrolment of over 950 treatment naïve genotype-1b patients in the pivotal Phase III interferon-free HCVerso™ 1 and 2 trials is complete.

15 Aug 2013

Intercept Pharmaceuticals reports financial results for Second quarter 2013

Intercept Pharmaceuticals, Inc. (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of novel bile acid therapeutics to treat chronic liver diseases, such as primary biliary cirrhosis, today reported financial results for the quarter and six months ended June 30, 2013 and announced presentations at an upcoming medical conference and upcoming investor conferences.

13 Aug 2013

Interferon-free treatment for genotype-1b hepatitis C patients: an interview with Professor Wulf Boecher, Boehringer Ingelheim

Genotype 1 is, worldwide, the most prevalent genotype of the hepatitis C virus. It accounts for around seventy percent of all hepatitis C infections.

30 Jul 2013

Hepatitis C (HCV) testing for baby boomers: an interview with Dr. Donald Jensen, Director, Center for Liver Diseases, University of Chicago

The USPSTF agreed with the CDC that since most patients (75%) who are currently infected with hepatitis C were born between 1945 - 1965, and since risk-based screening has not been successful in identifying these individuals, that a one time age-based hepatitis C blood test was necessary.

29 Jul 2013

World Hepatitis Alliance calls for urgent action to address viral hepatitis

On World Hepatitis Day, the World Hepatitis Alliance has called for urgent attention to be given to recent figures showing that although viral hepatitis kills as many as HIV/AIDS, the great majority of countries have no programmes in place to tackle it.

29 Jul 2013

GlaxoSmithKline receives CHMP positive opinion for REVOLADE

Ligand Pharmaceuticals Incorporated partner GlaxoSmithKline announced that today, the European Medicines Agency's Committee for Medicinal Products for Human Use issued a positive opinion recommending marketing authorization for GSK's REVOLADE (eltrombopag) as a treatment for low platelet counts (thrombocytopenia) in adult patients with chronic hepatitis C infection, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy

26 Jul 2013

WHO urges governments to act against five hepatitis viruses that cause severe liver infections

On World Hepatitis Day (28 July), the World Health Organization (WHO) is urging governments to act against the five hepatitis viruses that can cause severe liver infections and lead to 1.4 million deaths every year. Some of these hepatitis viruses, most notably types B and C, can also lead to chronic and debilitating illnesses such as liver cancer and cirrhosis, in addition to loss of income and high medical expenses for hundreds of millions of people worldwide.

24 Jul 2013

Par Pharmaceutical receives final ANDA approval for generic version of Trilipix

Par Pharmaceutical Companies, Inc. today announced that it has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for fenofibric acid EQ 45 mg and EQ 135 mg delayed-release capsules.

19 Jul 2013

Comprehensive analysis of disease burden in US

In nearly every major cause of premature death - from ischemic heart disease to diabetes to interpersonal violence - the United States trails its economic peers, according to new research from a global collaborative of scientists led by the Institute for Health Metrics and Evaluation at the University of Washington.

12 Jul 2013

Research reveals link between elevated BMI and increased risk of gallstone in women

New research reveals a causal association between elevated body mass index (BMI) and increased risk of gallstone disease. Results published in Hepatology, a journal of the American Association for the Study of Liver Diseases, show women are at greater risk of developing gallstones.

12 Jul 2013

PRISM Pharma announces closing of $15 million Series C financing

PRISM Pharma Co., Ltd., a drug discovery company focused on developing small molecule technologies that modulate protein-protein interactions, today announced the close of an approximately $15 million (approximately ¥1.4 billion) Series C financing.

13 Jun 2013

Investigational all-oral interferon-free combination from Boehringer Ingelheim achieves 95% viral cure rates in genotype-1b hepatitis C patients

New data from Boehringer Ingelheim’s interferon-free SOUND-C3 study were presented during the APASL Liver Week in Singapore. The Phase IIb study investigated the efficacy and safety of faldaprevir+ and deleobuvir+ (BI 207127) plus ribavirin in treatment-naïve patients with genotype-1b (GT-1b) hepatitis C virus (HCV),1 one of the most common types of HCV globally.2

13 Jun 2013

Cirrhosis News and Research

Latest Cirrhosis News and Research

Simple traffic light test helps reduce drinking rates in people with risk of liver disease

Smartphone app can quickly screen for cognitive dysfunction in patients with cirrhosis

Boehringer Ingelheim completes patient enrolment for interferon-free hepatitis C treatment

Hepatitis C services in the UK: an interview with Louise Campbell, senior liver nurse at Imperial College Healthcare NHS Trust

Peru: Liver cancer affects young people and children who do not have related risk factors

World Bank Group, IHME reports to help policymakers tackle health issues facing countries

Blocking a protein helps virus to thrive and restore immune function to fight HCV infection

Argininosuccinic aciduria (ASA) and gene therapy: an interview with Dr Julien Baruteau, UCL Institute for Women's Health, London

Boehringer Ingelheim completes patient enrolment of two pivotal Phase III interferon-free hepatitis C clinical trials

Intercept Pharmaceuticals reports financial results for Second quarter 2013

Interferon-free treatment for genotype-1b hepatitis C patients: an interview with Professor Wulf Boecher, Boehringer Ingelheim

Hepatitis C (HCV) testing for baby boomers: an interview with Dr. Donald Jensen, Director, Center for Liver Diseases, University of Chicago

World Hepatitis Alliance calls for urgent action to address viral hepatitis

GlaxoSmithKline receives CHMP positive opinion for REVOLADE

WHO urges governments to act against five hepatitis viruses that cause severe liver infections

Par Pharmaceutical receives final ANDA approval for generic version of Trilipix

Comprehensive analysis of disease burden in US

Research reveals link between elevated BMI and increased risk of gallstone in women

PRISM Pharma announces closing of $15 million Series C financing

Investigational all-oral interferon-free combination from Boehringer Ingelheim achieves 95% viral cure rates in genotype-1b hepatitis C patients

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Cirrhosis News and Research

Latest Cirrhosis News and Research

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in